secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001193125-23-173151
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics secures $25M Series B financing commitment, conditional on SPAC merger close
--------------------------------------------------------------------------------

- Series B financing: $25M total, led by Jackson Investment Group ($5M initial, $20M conditional on business combination).
- Calidi Cure, LLC (led by CEO Allan Camaisa) commits additional $12.5M in Series B preferred stock.
- Merger Agreement amended to allow Unused Continuation Shares and Sponsor Incentive Securities for PIPE or equity investments.
- Jackson Investment Group receives Voting and Lock-Up Agreement: 6-month lock-up, release if share price ≥$12.00 for 20 of 30 days.
- Proceeds to advance pipeline: CLD-101, CLD-201, CLD-202 allogeneic stem cell and oncolytic virus therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000119312523173151/0001193125-23-173151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000119312523173151/d521495d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-173151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer